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Background.  Diabetes  patients   are  at  high  risk for 
cardiovascular  disease. Evidence and  guidelines 
recommending the use of multiple cardiovascular 
medications  to support  the  management of diabetes 
have   been   well-established.  It  is  nevertheless  of 
growing concern that the benefits conferred by 
combination  of  the  drugs  are  potentially  o"set by 
perceived deterioration on health-related quality of life 
(HRQoL) attributable to pill burden. 
 
Objectives.  A  cross-sectional   study   was  conducted 
to determine the extent of use of cardiovascular 
medications  in elderly Australian women  with 
diabetes–either individually or in combination–for 
primary  and  secondary  prevention of cardiovascular 
disease. This study  further  examined  whether  usage 
patterns of cardiovascular medications  have e"ects on 
their health-related quality of life. 
 
Methods.  A subset  of  the  older  cohort  completing 
Survey  4  in  the  ALSWH  who  self-reported   to  have 
been diagnosed with diabetes  and/or  use medications 
indicative of diabetes  were selected  as study subjects. 
Use of cardiovascular medications  was identified  from 
self-reports on usage of medications  belonging to the 
Anatomical  Theraupetic Chemical  (ATC)  code  B01AC 
(platelet  aggregation inhibitors), C03 (diuretics), C07 
(β-blockers), C08 (calcium channel  blockers), C09 
(agents  acting  on the  renin-angiotensin system), C02 
(other antihypertensives) and C10 (lipid modifying 
agents).  Prevention   stage   of  cardiovascular  disease 
was determined by presence  of macrovascular disease 
identi#ed  from self-reports  of having  at least  one  of 
the following conditions: stroke, heart disease (angina, 
heart  attack,  other  heart  problems),  had  undergone 
or on  waiting  list for a heart  surgery  (heart  bypass, 
angioplasty, angiography), or on any of cardiac drugs 
(ATC code C01) or warfarin (ATC code B01AA). Patterns 
of cardiovascular  drug  use  were  classified as no use, 
using any antihypertensives, lipid lowering  agents  or 
antiplatelet drugs, using  any two  combinations, and 
using all the three classes of medications. Quality of life 
was measured with the  use of the  SF-36, focusing on 
the  physical functioning, general  health, vitality and 
mental   health   subscales.  Linear  regression   analyses 
of  survey  data  evaluated   the  associations  between 
usage patterns of cardiovascular medication  and 
individual subscales  of the SF-36 while controlling  for 
other sociodemographic, health  behaviour  and health 
service utilisation characteristics. 
 
Results. Of 7,158 older  women  retained  at Survey 4, 
885 were identified  as having diabetes  among  which 
390   (46.8%)   had   macrovascular    disease.   Twenty- 
three  percent  of the  diabetic  women  used  any  one 
category   of  antihypertensives,  lipid  lowering  drugs 
or antiplatelets, 37.5% reported use of a combination 
of any  two  and  29.1% were  on  all three  categories 
of medicines. Using at  least  one  cardiovacular  drug 
was  shown   to   be   associated   with  higher   HRQoL 
scores.  After adjustment  for other  covariates,  being 
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Figure 1. Cardiovascular medication use by presence of macrovascular disease. 
Panel A shows usage prevalences of antiplatelet, lipid lowering drug and 
antihypertensive classes. Panel B shows the overall pattern of cardiovascular 
drug use. Signi#cant estimate di$erences between the two groups (with & 
without MVD) are indicated by 
non-overlapped 95% CIs. Abbreviations: LLA, lipid lowering agent; CCB, 
calcium channel blocker; ACEI, angiotensin converting enzyme inhibitor; 
ARB, angiotensin II receptor blocker; AH, antihypertensive; MVD, 
macrovascular disease; CI, con#dence interval. 
 
Figure 2. Radar chart of the quality of life models. Di$erent markers 
connected with their corresponding lines represent regression coe"cients of 
each QoL subscales. A coe"cient of 0 means no associations between 
variables and QoL scores are found. Usages 
of cardiovascular medication are mostly shown to be subjectively 
bene#cial as markers reside in outer area, while other covariates are 
shown to have negative e$ects on QoL indicated by markers sitting within 
grey area. Abbreviations: QoL, quality of life; CAM, 
complementary and alternative medicines; GP, general practitioner 
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on triple combination of cardiovascular drugs was 
signi#cantly associated  with increased  scores on 
physical   functioning    (coe=cient   16.134,   95%   CI 
6.940, 25.327), general  health  (10.058, 95% CI  2.649, 
17.468)  and  mental   health   subscales   (12.896,  95% 
CI  6.562,  15.882). Being  on  any  dual  combination 
was  significantly   associated   with   increased   scores 
on   physical   functioning    (coe=cient   14.744,   95% 
CI  5.988, 23.501) and  general  health  (8.334,  95% CI 
1.200, 15.467), whereas  using  a single cardiovascular 
drug  is only  significantly  associated   with  increased 
score on physical functioning  (coe=cient 12.346, 95% 
CI  3.943,  20.750).  A negative  association  was  found 
between using three  cardiovascular drugs and vitality 
score albeit modest and statistically nonsigni#cant 
(coe=cient -1.342, 95% CI -7.927, 5.242). 
Conclusion.  The   use  of  cardiovascular   medications 
in elderly Australian women with diabetes  was 
reasonably  high  particularly for the  secondary 
prevention of cardiovascular  disease. Use of multiple 
cardiovascular  drugs  was demonstrated to  be 
subjectively  beneficial  in terms  of perceived  physical 
functioning, general  health  and  mental  health. There 
remains a possibility that being on more intensive 
regimens with more cardiovascular drugs will diminish 
patients’ HRQoL since the  remaining  subscales  of the 
SF-36 were not evaluated. If HRQoL in diabetics is to be 
more comprehensively assessed, there may be value in 
employing a diabetes-specific instrument as an add-on 
to the generic HRQoL instrument. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
